Skip to main content
ABT
NYSE Life Sciences

Abbott Settles Key Preterm Infant Formula Lawsuits for $670 Million, Reducing Legal Overhang

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$113.75
Mkt Cap
$197.506B
52W Low
$81.97
52W High
$137.49
52W Position info
39% above low
Off High info
17% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ABT sits 39% above its 52-week low of $81.97.

Summary

Abbott has settled a major portion of its preterm infant formula litigation for $670 million, resolving the high-profile Gill case and 2,000 other claims, which significantly reduces a key legal risk.


Key Events · Legal and Risk Events · ABT

  • Litigation Settlement

    Abbott agreed to pay approximately $670 million to resolve the "Gill" lawsuit and claims from about 2,000 other individuals related to its preterm infant formulas.

  • Risk Reduction

    This settlement addresses a significant legal overhang, including the $495 million "Gill" verdict (plus interest, totaling ~$600M) that was affirmed on appeal, converting a contingent liability into a fixed cost.

  • Remaining Claims

    Approximately 1,700 lawsuits involving 12,700 individual infants are still pending in federal and state courts, indicating ongoing, albeit reduced, legal exposure.


Analysis · ABT · Life Sciences

Abbott Laboratories has agreed to pay approximately $670 million to resolve the significant "Gill" lawsuit, which had an affirmed $495 million verdict, and an additional 2,000 related claims concerning its preterm infant formulas. This settlement, while a substantial payout, removes a major legal uncertainty and caps a previously elevated risk, as noted in the company's recent 10-Q. However, approximately 1,700 lawsuits involving 12,700 infants remain pending.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABT was trading at $113.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $197.5B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABT - Latest Insights

ABT
Nov 04, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $115.48
Real-time Price: $109.99 info
Change: -$5.49 (-5%) info
Market Cap: $191.397B info
ABT
Oct 21, 2026, 8:53 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $98.21
Real-time Price: $109.99 info
Change: +$11.78 (+12%) info
Market Cap: $191.397B info
ABT
Oct 21, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $99.52
Real-time Price: $109.99 info
Change: +$10.47 (+11%) info
Market Cap: $191.397B info
ABT
Oct 21, 2026, 7:32 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $100.55
Real-time Price: $109.99 info
Change: +$9.44 (+9%) info
Market Cap: $191.397B info
ABT
Oct 21, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.52
Real-time Price: $109.99 info
Change: +$9.47 (+9%) info
Market Cap: $191.397B info